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An ensemble of the iCluster method to
analyze longitudinal lncRNA expression
data for psoriasis patients
Suyan Tian1* and Chi Wang2,3*
Abstract
Background: Psoriasis is an immune-mediated, inflammatory disorder of the skin with chronic inflammation and
hyper-proliferation of the epidermis. Since psoriasis has genetic components and the diseased tissue of psoriasis is
very easily accessible, it is natural to use high-throughput technologies to characterize psoriasis and thus seek targeted
therapies. Transcriptional profiles change correspondingly after an intervention. Unlike cross-sectional gene expression
data, longitudinal gene expression data can capture the dynamic changes and thus facilitate causal inference.
Methods: Using the iCluster method as a building block, an ensemble method was proposed and applied to a
longitudinal gene expression dataset for psoriasis, with the objective of identifying key lncRNAs that can discriminate
the responders from the non-responders to two immune treatments of psoriasis.
Results: Using support vector machine models, the leave-one-out predictive accuracy of the 20-lncRNA signature
identified by this ensemble was estimated as 80%, which outperforms several competing methods. Furthermore, pathway
enrichment analysis was performed on the target mRNAs of the identified lncRNAs. Of the enriched GO terms or KEGG
pathways, proteasome, and protein deubiquitination is included. The ubiquitination-proteasome system is regarded as a
key player in psoriasis, and a proteasome inhibitor to target ubiquitination pathway holds promises for treating psoriasis.
Conclusions: An integrative method such as iCluster for multiple data integration can be adopted directly to analyze
longitudinal gene expression data, which offers more promising options for longitudinal big data analysis. A
comprehensive evaluation and validation of the resulting 20-lncRNA signature is highly desirable.
Keywords: Psoriasis, Long non-coding RNAs (lncRNAs), Longitudinal data, Integrative clustering (iCluster)
Background
Psoriasis is an immune-mediated, inflammatory disorder
of the skin with chronic inflammation, and hyper-
proliferation of the epidermis [1]. It is well supported
that psoriasis has genetic components. Based on this fea-
ture and because the diseased tissue is very easily
accessible, it is natural to characterize the molecular
profiles of psoriasis, and thus to investigate its pathogen-
esis and to develop its targeted immune therapies with
the aid of high-throughput technologies.
Long non-coding RNAs (lncRNAs) are post-
transcriptional and epigenetic regulators that have
lower expression levels and are more tissue-specific
compared with protein-coding genes [2]. Once regarded
as evolutionary junk, lncRNAs are now known to play
essential roles in many complex diseases, especially in
cancers [2]. However, their implication in psoriasis has
been rarely investigated and remains poorly understood.
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Among the limited amount of research carried out to ex-
plore the roles that lncRNAs may play in psoriasis, some
encouraging results show that lncRNAs are of essential
importance in this disease. For example, a very recent
study [3] genotyped single nucleotide polymorphisms
(SNPs) of antisense non-coding RNA in the INK4 locus
(ANRIL) in 286 patients with psoriasis and 300 controls,
and demonstrated that this lncRNA can be regarded as a
risk locus of psoriasis. Another study [4] showed mater-
nally expressed gene3 (MEG3), a competing endogenous
RNAs (ceRNA) of miR-21, was significantly downregu-
lated in lesional skin of psoriasis. Furthermore, by carrying
out the weighted gene correlation network analysis
(WGCNA) [5], a study [6] suggested that in psoriasis, in-
stead of acting alone many lncRNAs functioned coordi-
nately to impact its onset, progression, and treatment.
Transcriptional profiles not only vary under different
conditions or in different tissues but also change corres-
pondingly as a disease initializes and advances, or after
an intervention or a stimulus. Unlike cross-sectional
gene expression data (expression levels measured at a
single time point for each individual), longitudinal gene
expression data can capture such dynamic changes and
infer the causality relationship between these temporal
changes and the phenotype of interest. Consequently,
the amount of such data has increased dramatically. For
psoriasis alone, several longitudinal gene expression data
[7–10] have been stored in the GEO database, which
provides researchers a unique opportunity to explore
psoriasis deeply from different points of view. In [8], for
example, longitudinal gene expression profiles obtained
pre-treatment and at intermediate time-points were used
to predict the response of individual patients with psor-
iasis to immune treatments. After evaluating the predict-
ive accuracy of response status using single time point
and longitudinal data, it is concluded that the gain in
predictive accuracy resulting from including additional
time points is substantial.
In this study, a medium-sized longitudinal dataset [8]
was reanalyzed using the iCluster method [11], an inte-
grative clustering method that combines multiple omics
data for better characterization and segmentation of a
specific disease. The objective of this study is to identify
crucial lncRNAs which can explain the dynamic differ-
ences in between the responders and the non-
responders to a specific treatment, judged by the PASI75
index, an indicator of whether at least 75% reduction of
the Psoriasis Area & Severity Index (PASI) has been
achieved for 12 weeks or longer after being treated.
The iCluster method [11] was proposed by Shen et al.
to integrate multiple big genomics data together and
thus cluster the samples by using a joint latent variable
model. Subsequently, in order to eliminate or alleviate
drawbacks of the iCluster method (for example, the
original version can only model continuous genomic
data), the method itself has been updated or extended to
several versions since its initiation, e.g., iClusterPlus [12],
iClusterBayes [13], an iCluster extension that explicitly
includes an extra penalty term such as LASSO for the
purpose of relevant feature selection [14], and the Bayes-
ian factor analysis (GBFA) framework [15]. So far, the
iCluster method [11] and its updated versions have been
widely applied to analyze many genomics datasets that
cover a variety of cancers such as for glioblastoma [16]
and esophageal cancer [17].
In our opinion, longitudinal gene expression data can
be regarded as a special case of multiple omics data or
multiple-view data integration [18], with the expression
profiles at a single time point from the same individuals
being viewed as one of multiple data. In this article, we
show that direct utilization of an integrative analysis al-
gorithm such as the iCluster method [11] to longitudinal




A microarray dataset [8] whose accession number is
GSE85034 in the Gene Expression Omnibus (GEO)
database (https://www.ncbi.nlm.nih.gov/geo/) was used
to identify relevant lncRNA to predict the response sta-
tus of individual patients to immune treatments. There
were 179 arrays in this experiment, which involved the
gene expression profiles of 30 patients with moderate to
severe psoriasis at the baseline with both non-lesion
skins and lesion skins, and at weeks 1, 2, 4, and 16. Of
these 30 patients, half were treated with adalimumab
(ADA) and the other half were treated with methotrex-
ate (MTX). Of note, one patient who was on the ADA
arm had no expression level measured at week 16 given
his/her PASI score already achieved a reduction of 75%
at the week 4 (thus had been discharged). In Table S1,
demographic characteristics of the 30 patients were
presented.
The pre-processed data (ready for reanalysis) that were
quantile normalized were downloaded from the GEO
database. By matching the gene symbols of lncRNAs in
the GENCODE (https://www.gencodegenes.org/) data-
base (version 32) to those of genes annotated by the Illu-
mina HumanHT-12 V 4.0 bead chips, 662 unique
lncRNAs were identified, upon which the downstream
analysis was carried out.
iCluster
The integrative clustering method (iCluster) proposed
by Shen et al. [11] uses a joint latent variable model to
combine multiple omics data together and then cluster
samples into distinct groups. Briefly, in the model T
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genomic data matrix Xit (t=1, …, T) are related to a set
of latent variables Zi (i=1, …, n) in the following way,
Xit ¼ WtZi þ εit
here, Wt represents the coefficient of gene g for data
type t (here, for time point t) and εit is the error terms.
Conditioned on the latent variable Zi, Xit are independ-
ent from one another. The correlations of different gen-
omic data for the same people are modeled with these
latent variables. In the iCluster model, an expectation-
maximization (EM) algorithm is used for parameter esti-
mation. By using a soft-threshold method to continu-
ously shrink the coefficients of non-informative values
toward 0’s, the iCluster method [11] simultaneously ac-
complishes data integration, dimension reduction, fea-
ture selection, and then divides samples into different
subgroups according to the latent variables. Readers are
referred to the original article for a detailed description
of the iCluster method.
In this study, the iCluster/iClusterPlus method is
adopted to analyze longitudinal gene expression data
that involve four time points—lesional tissues at the
baseline, week 1, week 2, and week 4, with the objectives
of selecting important lncRNAs which can distinguish
responders from non-responders to a specific immune
therapy, revealing the underlying therapeutic mecha-
nisms of the treatment and thus detecting patients who
are highly likely to respond and thus benefit from the
treatment as early as possible. Consequently, instead of
representing multiple data types, the index t in the above
equation corresponds to time points.
The iCluster method is essentially an unsupervised
learning method whose predictive performance is usually
inferior to a supervised learning method. To address this
issue, by following the idea of an ensemble learning
method, we randomly selected a small subset of
lncRNAs (here, we set the size at 20 for a fast implemen-
tation) and performed clustering repeatedly by applying
the iCluster method to the resulting subsets for 10,000
times. Of note, we disabled feature selection of the
iCluster method by setting the tuning parameter λ’s to
zero. This consideration is based on the fact that we only
used a small subset of lncRNAs for each replicate. In
addition, the number of clusters in iCluster was set at
two given that the response status to a specific treatment
is the outcome of interest.
Then, we combined the resulting lncRNA lists of
learners whose accuracy is > 75%, and ranked the
lncRNAs according to self-customized scores which may
be used to evaluate the importance of certain lncRNAs
in the overall integrated “stronger” learner. These scores
were calculated by summing up a specific gene’s
absolute Wt values in those “weaker” iCluster learners.
For a specific gene, therefore, if |Wt|=0 for (t=1,…T)
then this gene would be ruled out. On the other hand, if
the sum of |Wt| is large enough, which may correspond
to two extreme cases—either the magnitude of |Wt| is
very large at a single time point or two or their values
are subtle at all time points but when added up together
the sum is large enough, the certain gene is subject to
temporal changes over time. Alternatively, the maximum
of |Wt| may be used to represent the importance of a
certain gene. However, it would lead to a high probabil-
ity of missing the latter scenario. We believe that this
strategy can help obtain a stronger and more robust
learner and identify core lncRNAs associated with the
outcome of interest. This procedure is referred to as the
iCluster ensemble hereafter, and the R codes of iCluster
ensemble have been restored in the Github repository
(https://github.com/windytian/icluster_ensemble-).
Statistical language and packages
All statistical analyses were carried out in the R lan-
guage, version 3.6.1 (http://www.r-project.org), with the
aid of Bioconductor packages and CRAN packages. Spe-
cifically, iClusterPlus [11, 12] was used for iCluster ana-
lysis, org.Hs.eg.db for gene annotation, and EDGE for
EDGE analysis [19], pheatmap [20] to generate heat-
maps, locfit [21] for local regression fitting, glmnet [22]
for LASSO analysis, gee (https://cran.r-project.org/web/
packages/gee/gee.pdf) for fitting the GEE models, and
e1071 (https://cran.r-project.org/web/packages/e1071/e1
071.pdf) for support vector machine modeling.
Results
Using the majority of voting (for each replicate), the pre-
diction of response status for all samples was made. If
the number of predicting the sample as a responder is
more than that of non-responder, then the specific sam-
ple is classified as a responder (vice versa), the iCluster
ensemble of 10,000 replicates resulted in an overall ac-
curacy of 83.33%, with 5 responders being misclassified
as non-responders (2 were on MTX treatment and 3 on
ADA). Notably, if only the learners with accuracy >80%
were considered, the final accuracy was increased
slightly to 86.67%. Nevertheless, given there were only 6
leaners that met this stringent cutoff and most lncRNAs
within these 6 leaners only appeared once (mostly sub-
ject to the randomness), a less stringent cutoff was
chosen.
Ranking decreasingly according to the self-defined
scores in the “Materials and Methods” section, we se-
lected the first 20 lncRNAs as core genes to build up a
classification model and predict the response status of a
psoriasis patient to a specific immune therapy. Table 1
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presents the gene symbols of the identified 20 lncRNAs
on the list.
Of the 20 lncRNAs on the list, LINC00936 (also
known as ATP2B1-AS1) ranked at the top. In the litera-
ture, we cannot find evidence to link this lncRNA to
psoriasis. Future experimental validation of its role in
psoriasis is highly desirable. However, the lncRNADi-
sease 2.0 knowledgebase [23] suggested this lncRNA was
experimentally validated to correlate with astrocytoma
and computationally predicted to associate with several
other cancer types. In that validation study [23],
ATP2B1-AS1 was identified as a differentially expressed
gene in astrocytoma using a microarray experiment.
Additionally, using the GeneCards database [24], the
biological relevance of all 20 lncRNAs was evaluated and
this information is also given in Table 1. Actually, only
CD27-AS1 and H19 were indicated to directly relate to
psoriasis, and seven other lncRNAs were indirectly re-
lated to psoriasis.
The heatmap of average expression values for the 20
lncRNAs across the baseline (lesional skin), week 1,
week 2, and week 4 is shown in Fig. 1a, from which, it is
observed that the responders and non-responders may
be clustered into several separate communities by the
hierarchical clustering method. When the number of
clusters was set at 2, about 11 patients were misclassi-
fied, resulting in an unsatisfactory performance. Thus,
we resorted to a supervised method for a more precise
segmentation between the responders and the non-
responders. Specifically, using support vector machine
(SVM) models and leave-one-out (LOO) method (one
sample has been left out, the iCluster ensemble was
trained on the remaining 29 samples and then the top
20 lncRNAs were selected), the predictive accuracy of
the iCluster ensemble (still, the average expression
values of lncRNAs before week 4 were used to generate
pseudo-genes that served as the covariates) was calcu-
lated as 80%, with 5 responders misclassified as non-
responders and one non-responder as responders. Fur-
thermore, the heatmap of actual expression values for
the 20 lncRNAs at these four time points is presented in
Fig. 1b, from which the similar pattern that the re-
sponders and non-responders are mixed together is
observed.
To investigate the predictive capacity of the resulting
20-lncRNA list, we have randomly selected a set of 20
lncRNAs for 1000 times. Subsequently, SVM models
were fit on the LOO data using the randomly selected
20 lncRNAs as predictors, and then the predictive accur-
acies for these 1000 replicates were calculated and aver-
aged. The baseline accuracy of a 20-gene list is
estimated as 53.47%. Therefore, the 20-gene list identi-
fied by the iCluster ensemble outperforms the randomly
selected 20-gene list.
Furthermore, a comparison between the iCluster en-
semble and three competing methods, namely, iCluster
(using all 662 lncRNAs), LASSO [25], an ensemble with
LASSO as the basic learner, GEE-based screening [26],
and EDGE [19] were made. For a comparison with
iCluster, the effect of ensemble can be evaluated. As ex-
pected, a single run of iCluster alone resulted in an un-
satisfied performance, which is identical to that of
LASSO. Even though iCluster can analyze multi-view
data, its nature of being an unsupervised learning
method introduced many noises.
For the GEE-based screening (the working correlation
structure was fixed at the unstructured one since the
time points are unequally spaced), GEE models with un-
structured working correlation structure were fit for in-
dividual genes and the top 20 lncRNAs (most
significant) were selected. Upon the 20-gene list, LOO
support vector machine models were fit to calculate the
predictive error rate, which is estimated as 33.33% and is
Table 1 The 20-lncRNA list identified by the iCluster ensemble
Gene symbol Score used to evaluate








PCED1B-AS1 4.73 I (0.91)
SCARNA9 3.87 I (0.18)
TMEM99 3.03 I (0.02)
H19 2.89 D (0.18)
LINC00640 2.65
PAXIP1-AS1 2.63
MAPKAPK5-AS1 2.02 I (0.11)
DICER1-AS1 1.92 I (0.04)
MIR600HG 1.9
SNHG7 1.82 I (0.1)
ZMIZ1-AS1 1.79 I (0.08)
TMCC1-AS1 1.75




Note: D, directly related to psoriasis according to the GeneCards database; I,
indirectly related to psoriasis according to the GeneCards database. The
confidence scores are indicative of how much evidence supports the
biological relevance, with a higher value corresponding to a stronger support
aA self-defined score is calculated as the sum of absolute weights over the
replicates of iCluster modeling, which is used to determine if a certain gene
should be selected in the final model. For more details, please refer to the
“Materials and Methods” section
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inferior to the 20% achieved by the iCluster ensemble
method.
As a specific feature-selection method to handle longi-
tudinal data, the EDGE method (which is also a filter
method) has been widely utilized. When setting the cut-
off value of FDR at 0.05, 27 lncRNAs were deemed as
differentially expressed genes across time between the
responder group and the non-responder group by the
EDGE method. Then, LOO SVM models were fit to esti-
mate predictive accuracy of the 27-gene list, whose value
is 56.67%.
Specifically, LASSO is an embedded method that iden-
tifies relevant features and constructs the final classifier
simultaneously. In order to fit LASSO, the longitudinal
expression profiles need to be downgraded as cross-
sectional expression profiles by calculating the averages
of each gene across time points. For this application,
most LASSO methods select no lncRNAs at all (which
corresponds to the null model), resulting in an error rate
of 46.67%, which is very close to a random guess. Fur-
thermore, we replaced iCluster with LASSO to frame
LASSO-ensemble in which a LASSO logistic model was
used as the basic learner to identify relevant lncRNAs
among randomly selected 100 genes. Based on the sum
of estimated coefficients for the 10,000 replicates, the
top 20 lncRNAs were selected. Then LOO SVM models
were fit to estimate predictive accuracy of the LASSO
ensemble, whose value is 73.33%, presenting a substan-
tial improvement over LASSO. The results of this
comparison are presented in Table 2. Overall, iCluster-
ensemble outperformed the competing methods.
Based on the above comparison, we concluded that the
superiority of iCluster-ensemble may be due to two as-
pects: one is a method capable of analyzing longitudinal
Fig. 1 Heatmap of identified 20 lncRNAs expression profiles. a Heatmap of the average expression values across four time points for the 20
lncRNAs. b Heatmap of actual expression values at individual time points for the 20 lncRNAs. Type: response status, corresponding to the
responder group and the non-responder group that were colored by red and green, respectively. From plot A, it is observed that the responders
and non-responders may be clustered into several separate communities by the hierarchical clustering method. If the number of clusters was set
at 2, eleven patients were misclassified, resulting in an unsatisfactory performance. In plot B, the similar pattern has been observed. Of note, the
expression values have been normalized to have a mean of 0 and a variance of 1, for a clearer representation of these 20 lncRNAs. The color bars
on the right side indicate the ranges of gene expression values, with red for high expression values and blue for low expression values
Table 2 Comparison between iCluster-ensemble and
competing methods





iCluster-ensemble Yes 20 20%
iCluster Yes 20 46.47%
GEE-based screening Yes 20 33.33%
EDGE Yes 27 43.33%
LASSO No 0.43a 46.67%
LASSO-ensemble Yes 20 26.67%
aSince LASSO builds up the final model simultaneously with feature selection,
the sizes of final model differ in single LOO runs. Here, the average of the
sizes over resulting 30 LASSO models is given. Predictive error corresponds to
the leave-one-out error (LOO) rate
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data and the ensemble that enables to abstract a stronger
learner from weak learners. Moreover, the contribution of
an ensemble may be substantially bigger, while it also
addresses the drawback of iCluster being an unsuper-
vised learning method. In addition, since the relevant
biomarkers for the two treatments may differ, separ-
ate analyses stratified by treatments using iCluster-
ensemble were also performed, and the results are
given in Table S2.
Another application of the iCluster-ensemble proced-
ure on a longitudinal microarray dataset of patients with
multiple sclerosis was made, and the analysis results
were presented in Supplementary File 1. Basically, the
results (Table S3) consist with the results of the psoriasis
application, namely, iCluster-ensemble performs the best
among the competing methods.
Using the loess (local regression) method, the change
trajectories of identified lncRNAs’ expression profiles
stratified by the response status were made (including
the top three genes and those that were indicated to be
biologically relevant to psoriasis, reducing the number of
lncRNAs under consideration to 12), and are presented in
Fig. 2. From this figure, we observed that for the responder
group, the gaps between lesional skins (LS) and non-
lesional (NL) skins had closed up as the time advanced.
This pattern became apparent even at week 4. All expres-
sion changes of the identified 20 lncRNAs except FRMD
EAS1 possessed this pattern. The certain temporal change
Fig. 2 Change trajectories of 12 lncRNAs’ expression values over time stratified by the response status. In these plots, x-axis represents the time
points measured, and y-axis represents the expression values. The averages of certain lncRNAs at separate time points were connected to a curve
to represent their respective change trajectories over time. It is observed that for the responder group, most genes’ expression values moved
back toward the expression values of non-lesional skins. This pattern became very apparent at week 4 and later. For the non-responder group,
this pattern is much less apparent. NR, the non-responder group; R, the responder group; NL, non-lesional skin at the baseline; LS, lesional skin at
the baseline; 1, lesional skin at week 1; 2, lesional skin at week 2; 4, lesional skin at week 4; 16, lesional skin at week 16
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pattern over time in the responder group suggested the
expression level of these lncRNAs recovered to their re-
spective normal values; thus, these lncRNAs may have
prognostic values on the response status indeed. As an ex-
ample, for H19, the average expression value for non-
lesional skin is 7.405, while it reached the plateau (the mini-
mum) for baseline lesional skin, the average expression
level turned up back and monotonically increased, even
surpassed the non-lesional level and climbed up to 8.188 at
week 16 in the responder group. In contrast, the U-shape
in the non-responder group has much less curvature. Actu-
ally, it looks more like a horizontal line.
Lastly, the target mRNAs by these 20 lncRNAs were re-
trieved from the lncRNADisease 2.0 knowledgebase [23]
and fed into the String software [27] for the enrichment ana-
lysis of KEGG pathways [28] and GO terms [29]. Five GO
biological process terms, three GO molecular function
terms, nine GO cellular component terms, and one KEGG
pathway were enriched by the target mRNAs. Those
enriched terms and pathways are given in Table 3. Among
these enriched terms or pathways, proteasome and protein
deubiquitination appeared several times. The ubiquitination-
proteasome system is regarded as a key player in psoriasis,
and a proteasome inhibitor to target ubiquitination pathway
holds promises for treating psoriasis [28].
Discussion
As far as psoriasis is concerned, the research on its rele-
vant lncRNA markers is really rare, explaining why in
the lncRNADisease 2.0 knowledgebase [23], a search on
lncRNAs that have been experimentally validated to as-
sociate with psoriasis returned nothing. Focusing on the
20 lncRNAs identified by the iCluster ensemble, the
lncRNADisease 2.0 knowledgebase [23] suggested that
only H19 was predicted to be associated with psoriasis
by some computational methods. Overall, the literature
mining and the lncRNA canonical knowledgebase search
found limited valuable information on the roles that this
20-lncRNA signature may play in combating psoriasis.
It is worth pointing out that there are several limi-
tations in this study. First, the sample size is not very
large. Stratified by the treatment arms, there were
only 15 patients in each stratum. Given these two
treatments may differ in terms of underlying thera-
peutic mechanisms and targeted molecular markers or
pathways, separate analyses stratified by treatment
arms were conducted and the results are presented in
the Additional file 1.
Second, this study had not been carried out in a spe-
cific platform for lncRNAs. As a result, some crucial
lncRNAs for psoriasis may be absent in this analysis. For
Table 3 Enriched pathways by target mRNAs of the 20-lncRNA list
ID Description Observed gene count Background gene count False discovery rate
GO: cellular component
GO:0005839 Proteasome core complex 7 21 <0.0001
GO:0019773 Proteasome core complex, alpha-subunit complex 6 8 <0.0001
GO:0000796 Condensin complex 5 7 <0.0001
GO:0000799 Nuclear condensin complex 2 3 0.0033
GO:1904813 Ficolin-1-rich granule lumen 4 125 0.0213
GO:0043232 Intracellular non-membrane-bounded organelle 24 4005 0.0302
GO:0044444 Cytoplasmic part 43 9377 0.0302
GO:0000932 P-body 3 81 0.0475
GO:0005737 Cytoplasm 48 11238 0.0475
GO: molecular function
GO:0004298 Threonine-type endopeptidase activity 7 21 <0.0001
GO:0005031 Tumor necrosis factor-activated receptor activity 3 25 0.0092
GO:0070011 Peptidase activity, acting on L-amino acid peptides 8 603 0.0362
GO: biological process
GO:0007076 Mitotic chromosome condensation 5 15 <0.0001
GO:0010032 Meiotic chromosome condensation 4 5 <0.0001
GO:0016579 Protein deubiquitination 7 275 0.0099
GO:0006323 DNA packaging 6 195 0.0111
GO:0043687 Post-translational protein modification 7 365 0.0253
KEGG pathway
hsa03050 Proteasome 7 43 <0.0001
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example, psoriasis associated non-protein coding RNA
induced by stress (PRINS) which has been shown to ex-
hibit the highest expression levels in non-psoriatic skin
lesions and play an important role in pathogenesis of
psoriasis does not belong to the 662 lncRNAs under
consideration in this study. As aforementioned, lncRNA
investigations on psoriasis are rare, let alone here, we
considered a longitudinal study. To the best of our
knowledge, the present study is among the first effort to
explore the association between lncRNAs and psoriasis
using longitudinal gene expression data.
Lastly, the predictive performance of the identified
20-lncRNA list was not validated on an independent
dataset, resulting in a potential overestimation. This is
due to the shortage of an independent dataset that
has same or similar objectives and study design, in
addition to a decent sample size. A large longitudinal
lncRNA study is needed to reveal the therapeutic
mechanism of an immune treatment for psoriasis and
thus predict the response status as early as possible,
from the perspective of lncRNAs.
Conclusions
In addition to being viewed as a gene set [30–32], longi-
tudinal gene expression profiles can be regarded as a
special case of multiple data sets/multiple-view data.
Consequently, many integrative methods that combine
those multiple omics data together such as [31, 32] may
be adopted directly to analyze longitudinal data. Direct
utilization of existing methods saves time and resources
to develop new statistical methods to specifically handle
longitudinal big data.
In this study, a well-known integrative clustering
method, namely, the iCluster method was used re-
peatedly to devise an ensemble for longitudinal
microarray data analysis, with the objective of identi-
fying relevant lncRNAs to predict response status of
psoriasis patients to immune therapies. Using the
iCluster ensemble and longitudinal lncRNA expression
values during the early period of treatments for pa-
tients with psoriasis, our analysis highlighted 20
lncRNAs that may hold predictive values for distin-
guishing between the responders and the non-
responders to immune treatment. Further investiga-
tion on these 20 lncRNAs to reveal comprehensively
how they function in concert triggered by immune
treatment to fight psoriasis is warranted.
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